Caramelli B, de Bernoche C Y, Sartori A M, Sposito A C, Santos R D, Monachini M C, Strabelli T, Uip D
Heart Institute (InCor) and AIDS Clinic, University of São Paulo Medical School, São Paulo, Brazil.
Braz J Infect Dis. 2001 Dec;5(6):332-8. doi: 10.1590/s1413-86702001000600007.
Hyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI). This study was initiated to analyze the modifications on blood lipids in HIV-patients receiving PI and the safety and efficacy of the treatment with fenofibrate. Total (TC) and HDL-cholesterol, triglycerides (TG), and CD(4)(+) T-cell counts were measured in 30 HAART-naive patients (Group I) before and after PI introduction. In a second phase of the study, the effects of fenofibrate on lipids, CPK, CD(4)(+), and viral load were determined in 13 patients (Group II) with elevated TC or TG. In Group I, 60% of the patients showed TC or TG elevations. Average increments of 31% and 146% in TC and TG respectively (p<0.0006 and p<0.0001) were observed. In Group II, fenofibrate treatment was associated with decrements of 6.6% (TC) and 45.7% (TG) (p=0.07 and 0.0002) and no modifications on CPK, CD(4)(+), and viral load. In conclusion, hyperlipidemia is common during the treatment of HIV with protease inhibitors, and fenofibrate appears to be an effective and safe choice for its treatment.
高脂血症经常被记录为用蛋白酶抑制剂（PI）治疗HIV患者的一种副作用。开展这项研究是为了分析接受PI治疗的HIV患者血脂的变化以及非诺贝特治疗的安全性和有效性。在30例初治抗逆转录病毒治疗（HAART）患者（第一组）引入PI之前和之后测量总胆固醇（TC）、高密度脂蛋白胆固醇、甘油三酯（TG）以及CD4(+) T细胞计数。在研究的第二阶段，在13例TC或TG升高的患者（第二组）中确定非诺贝特对血脂、肌酸磷酸激酶（CPK）、CD4(+)和病毒载量的影响。在第一组中，60%的患者出现TC或TG升高。分别观察到TC和TG平均升高31%和146%（p<0.0006和p<0.0001）。在第二组中，非诺贝特治疗使TC降低6.6%，TG降低45.7%（p=0.07和0.0002），并且对CPK、CD4(+)和病毒载量无影响。总之，在用蛋白酶抑制剂治疗HIV期间高脂血症很常见，非诺贝特似乎是其治疗的一种有效且安全的选择。
